Dr. Chung has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Gilead and Actelion, and research funding from Gilead, United Therapeutics, and Pfizer.
2151-4658/asset/olbannerleft.gif?v=1&s=75d1dd4933b4687fdb365bb32190b0a4ef453ee7)
2151-4658/asset/olbannerright.gif?v=1&s=a36ba6af41bd9af370864f6461a516746a709d31)
Systemic Sclerosis
Dyspnea assessment and pulmonary hypertension in patients with systemic sclerosis: Utility of the University of California, San Diego, Shortness of Breath Questionnaire
Article first published online: 26 FEB 2013
DOI: 10.1002/acr.21827
Copyright © 2013 by the American College of Rheumatology
Additional Information
How to Cite
Chung, L., Chen, H., Khanna, D. and Steen, V. D. (2013), Dyspnea assessment and pulmonary hypertension in patients with systemic sclerosis: Utility of the University of California, San Diego, Shortness of Breath Questionnaire. Arthritis Care Res, 65: 454–463. doi: 10.1002/acr.21827
- †
Dr. Chung has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Gilead and Actelion, and research funding from Gilead, United Therapeutics, and Pfizer.
- ‡
Dr. Khanna has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Gilead, Actelion, Bayer, Roche, DIGNA, Pfizer, and Sanofi-Aventis, research funding from Gilead and Actelion, and serves on the Speakers' Bureau of Actelion and United Therapeutics.
- §
Dr. Steen has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Gilead, Actelion, United Therapeutics, Roche, and Sanofi-Aventis, has served on the Speakers' Bureau for Actelion and Gilead, has served as a consultant for Gilead and United Therapeutics, and has received research funding from Actelion, Gilead, Pfizer, and United Therapeutics.
Publication History
- Issue published online: 21 FEB 2013
- Article first published online: 26 FEB 2013
- Accepted manuscript online: 6 OCT 2012 10:26AM EST
- Manuscript Accepted: 1 AUG 2012
- Manuscript Received: 2 APR 2012
Funded by
- Actelion
- Scleroderma Foundation
- Sibley Foundation
- Gilead
- Scleroderma Research Foundation
- Karen Brown Scleroderma Foundation
- Abstract
- Article
- References
- Cited By
Abstract
Objective
The University of California in San Diego Shortness of Breath Questionnaire (UCSD SOBQ) has been used to assess dyspnea-related activity limitation in patients with airway and parenchymal lung disease. We sought to assess the construct validity and responsiveness of the UCSD SOBQ in systemic sclerosis (SSc; scleroderma) patients with incident pulmonary hypertension (PH) and those at high risk of developing PH.
Methods
We used data from 179 patients enrolled in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry with pre-PH (defined by criteria on pulmonary function tests and/or echocardiogram) or definite PH with mean pulmonary artery pressure ≥25 mm Hg by right-sided heart catheterization within 6 months of enrollment. For this analysis, we included those subjects with complete data for self-reported measures at baseline and at 12 months.
Results
At baseline, the UCSD SOBQ had strong correlations in the expected direction with the disability index (DI) of the Health Assessment Questionnaire (HAQ) (r = 0.71, P < 0.0001), dyspnea assessment by visual analog scale (r = 0.71, P < 0.0001), and the Short Form 36 (SF-36) health survey physical component summary (PCS) score (r = −0.77, P < 0.0001), as well as a moderate correlation with the 6-minute walk test distance (r = −0.33, P < 0.0001), Borg dyspnea score (r = 0.47, P < 0.0001), and diffusing capacity of carbon monoxide (r = −0.33, P < 0.0001). Change in the UCSD SOBQ at 12 months correlated in the expected direction with change in the HAQ DI (r = 0.54, P < 0.0001) and change in the SF-36 PCS (r = −0.44, P < 0.0001). Multivariate analysis adjusting for age, sex, and race identified male sex as a significant predictor of death (odds ratio [OR] 7.00, 95% confidence interval [95% CI] 1.55–31.76), while the UCSD SOBQ showed a strong trend toward significance (OR 1.82, 95% CI 0.97–3.41).
Conclusions
The UCSD SOBQ demonstrates good construct validity and responsiveness to change in SSc patients with pulmonary vascular disease.